Galmed Pharmaceuticals Ltd
GLMD0.880USD
+0.000+0.03%
收盤 12/24, 13:00（美東）報價延遲15分鐘
4.82M總市值
虧損本益比TTM
關於 Galmed Pharmaceuticals Ltd 公司
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Galmed Pharmaceuticals Ltd簡介
公司代碼GLMD
公司名稱Galmed Pharmaceuticals Ltd
上市日期Mar 13, 2014
CEOBaharaff (Allen)
員工數量3
證券類型Ordinary Share
年結日Mar 13
公司地址16 Tiomkin Street
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編6578317
電話97236938448
網址https://www.galmedpharma.com
公司代碼GLMD
上市日期Mar 13, 2014
CEOBaharaff (Allen)
Galmed Pharmaceuticals Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
3.12K
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Citadel Advisors LLC
0.71%
Baharaff (Allen)
0.52%
Two Sigma Investments, LP
0.30%
Nehemya (Guy)
0.09%
Stenzler (Yohai)
0.09%
其他
98.30%
持股股東
持股股東
佔比
Citadel Advisors LLC
0.71%
Baharaff (Allen)
0.52%
Two Sigma Investments, LP
0.30%
Nehemya (Guy)
0.09%
Stenzler (Yohai)
0.09%
其他
98.30%
股東類型
持股股東
佔比
Hedge Fund
1.00%
Individual Investor
0.92%
Investment Advisor
0.04%
其他
98.04%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
29
75.58K
1.38%
-16.12K
2025Q2
36
135.24K
2.48%
+20.85K
2025Q1
40
122.99K
5.45%
+7.20K
2024Q4
44
74.98K
4.98%
+4.09K
2024Q3
46
26.83K
4.31%
-41.91K
2024Q2
47
54.30K
10.41%
+4.14K
2024Q1
52
35.65K
7.07%
-49.52K
2023Q4
54
66.85K
19.98%
-30.97K
2023Q3
59
78.73K
21.96%
+19.78K
2023Q2
57
33.03K
13.93%
-6.52K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baharaff (Allen)
36.94K
0.67%
+8.83K
+31.44%
Mar 21, 2025
Nehemya (Guy)
6.28K
0.11%
+6.25K
+20164.52%
Mar 21, 2025
Stenzler (Yohai)
6.28K
0.11%
+6.25K
+20164.52%
Mar 21, 2025
Cohen (Doron)
6.25K
0.11%
+6.23K
+36664.71%
Mar 21, 2025
Nir (Shmuel)
3.40K
0.06%
+3.12K
+1148.16%
Mar 21, 2025
Sidransky (David)
3.12K
0.06%
+3.08K
+7338.10%
Mar 21, 2025
Poshinski (Amir)
3.12K
0.06%
+3.12K
--
Mar 21, 2025
Nomura Investment Management Business Trust
1.70K
0.03%
--
--
Jul 31, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
公告日期
類型
比率
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
常見問題
Galmed Pharmaceuticals Ltd的前五大股東是誰？
Galmed Pharmaceuticals Ltd的前五大股東如下：
Baharaff (Allen)持有股份：36.94K佔總股份比例：0.67%。
Nehemya (Guy)持有股份：6.28K佔總股份比例：0.11%。
Stenzler (Yohai)持有股份：6.28K佔總股份比例：0.11%。
Cohen (Doron)持有股份：6.25K佔總股份比例：0.11%。
Nir (Shmuel)持有股份：3.40K佔總股份比例：0.06%。
Baharaff (Allen)持有股份：36.94K佔總股份比例：0.67%。
Nehemya (Guy)持有股份：6.28K佔總股份比例：0.11%。
Stenzler (Yohai)持有股份：6.28K佔總股份比例：0.11%。
Cohen (Doron)持有股份：6.25K佔總股份比例：0.11%。
Nir (Shmuel)持有股份：3.40K佔總股份比例：0.06%。
Galmed Pharmaceuticals Ltd的前三大股東類型是什麼？
Galmed Pharmaceuticals Ltd 的前三大股東類型分別是：
Citadel Advisors LLC
Baharaff (Allen)
Two Sigma Investments, LP
Citadel Advisors LLC
Baharaff (Allen)
Two Sigma Investments, LP
有多少機構持有Galmed Pharmaceuticals Ltd(GLMD)的股份？
截至2025Q3，共有29家機構持有Galmed Pharmaceuticals Ltd的股份，合計持有的股份價值約為75.58K，占公司總股份的1.38% 。與2025Q2相比，機構持股有所增加，增幅為-1.10%。
哪個業務部門對Galmed Pharmaceuticals Ltd的收入貢獻最大？
在--，--業務部門對Galmed Pharmaceuticals Ltd的收入貢獻最大，創收--，占總收入的--% 。
